Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41

Vaccine. 2007 Mar 1;25(11):2074-84. doi: 10.1016/j.vaccine.2006.11.025. Epub 2006 Nov 28.


Replication-defective adenovirus vectors, primarily developed from serotype 5 (Ad5) viruses, have been widely used for gene transfer and vaccination approaches. Vectors based on other serotypes of adenovirus could be used in conjunction with, or in place of, Ad5 vectors. In this study, Ad41, an enteric adenovirus usually described as 'non-cultivable' or 'fastidious,' has been successfully cloned, rescued and propagated on 293-ORF6 cells. The complementation capabilities of this cell line allow generation of Ad41 vectors at titers comparable to those obtained for Ad5 vectors. Mice immunized with an Ad41 vector containing an HIV envelope (Env) gene mounted anti-Env cellular and humoral immune responses. Ad41-Env vectors appear to be particularly attractive when used in heterologous prime-boost regimens, where they induce significantly higher cellular immune responses to HIV-Env than Ad5-based regimens. Ad41-based constructs are attractive vaccine vectors alone or in combination with Ad5 adenovectors, since each vector type can provide circumvention of pre-existing immunity to the other.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • AIDS Vaccines / genetics*
  • AIDS Vaccines / immunology*
  • Adenoviridae / genetics*
  • Adenoviridae / growth & development
  • Animals
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • Cell Line
  • Cytokines / biosynthesis
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Genetic Vectors*
  • HIV Antibodies / blood
  • HIV Envelope Protein gp120 / immunology
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Models, Animal
  • Molecular Sequence Data
  • Vaccination
  • Vaccines, Synthetic / immunology


  • AIDS Vaccines
  • Cytokines
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • Vaccines, Synthetic